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Abstract
Background: Simultaneous transapical implantation of transcatheter heart valves in the native mitral and aortic
position may be considered as an alternative to surgical valve replacement in high-risk patients presenting with
combined valve disease.
Case presentation: A 59-year-old female with severe aortic stenosis, severe mitral stenosis with mild mitral insufficiency,
persistent atrial fibrillation, severe chronic obstructive pulmonary disease and NYHA class of IV was evaluated
by our interdisciplinary heart team. Due to the calculated Euroscore II, logistic Euroscore with 10% and 17% a
decision was made towards a transapical TAVI approach. The implantation of a Sapien 3 (Edwards Lifesciences) valve in
the aortic position was performed and the perioperative TEE showed a good result. The preoperative imaging revealed
a narrow LVOT with risk for post interventional left ventricular outflow tract obstruction. Accordingly, it was decided
against the use of balloon-expanding valves for the mitral valve position in the interdisciplinary team, as it is
not repositionable. Instead, it was decided for the use of a Lotus (Boston Scientific) valve, as it is repositionable and
therefore possible to retract in case of LVOT obstruction. In the present case of double valve intervention, the
implantation attempt of a fully repositionable transcatheter heart valve into the native mitral annulus resulted
in acute LVOT obstruction requiring immediate removal of the device. The patient was extubated and experienced
uneventful postoperative recovery.
Conclusions: The case shows that improved preoperative work-up is necessary for better prediction of significant
LVOT obstruction following transcatheter mitral valve implantation. In borderline cases, the use of a fully repositionable
device is preferred.
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Background
Transapical transcatheter aortic and mitral valve implant-
ation (TA-AVI, TA-MVI) has become an attractive alter-
native to surgical valve replacement in high-risk patients
presenting with significant aortic and mitral valve path-
ology [1]. However, only limited clinical experience is
available so far and peri-procedural complication rate may
be significant [2, 3].
Technical reasons may restrict the use of TAMVI,
including optimal valve positioning, stable device
anchoring precluding later valve migration [4], anatom-
ical considerations such as the risk of left ventricular
outflow tract (LVOT) obstruction and the occurrence of
paravalvular leak in the D shaped mitral annulus [5]. For
this purpose, the use of a repositionable device is a safe
option to master the most important intra-procedural
problems [6].
Case presentation
A 59-year-old female highly symptomatic patient (func-
tional class NYHA IV) with severe aortic and mitral
valve stenosis combined to mild mitral regurgitation,
was evaluated for a valve procedure by the institutional
heart-team. She had undergone previous open mitral
commissurotomy in 1979, and percutaneous mitral
balloon valvuloplasty in 1989 and 2001. She suffered from
persistent atrial fibrillation, severe chronic obstructive
pulmonary disease, sleep apnea syndrome. Surgical valve
replacement was deemed high risk, since she presented
with a porcelain ascending aorta as well as massive
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calcifications of the left atrial wall (Fig. 1. a/b). Euroscore
II and logistic Euroscore score were 10% and 17% respect-
ively. Decision was made towards a transapical approach
as a double-valve procedure. Preoperative imaging includ-
ing angio-CT and transesophageal echocardiography
(TEE) is demonstrated in Fig. 1. The mean transvalvular
aortic gradient was 55 mmHg and the residual effective
valve orifice area was 0.4 cm2. The preoperative left
ventricular ejection fraction (LVEF) was measured at 55%.
Furthermore, preoperative TEE revealed a LVOT diameter
of 17 mm and a thickness of the subaortic septum at
14 mm. The aortic annulus perimeter 72.7 mm and
perimeter-derived diameter 23.1 mm was measured
using OsiriX MD DICOM viewer (© Pixmeo SARL)
and 3Mensio (Pie Medical Imaging). The mitral valve
showed a mean gradient of 12 mmHg with a residual
valve orifice area of 0.57 cm2 calculated according to
the pressure half-time method. Maximal diameter of
the left ventricular outflow tract was 19 mm (Fig. 1.c).
The aorto-mitral angle (AMA) was measured with
109° (Fig. 1 b) by 3Mensio (Pie Medical Imaging).
The preoperative coronary angiogram revealed no
signs of coronary artery disease. Furthermore, the
examination revealed a moderate to severe post-
capillary pulmonary hypertension with a mean of
44 mmHg.
The procedure was performed under general anesthesia
utilizing both fluoroscopy and transesophageal echo-
cardiography. A left mini-thoracotomy incision in
the 5th intercostal space, pre-dilatation of the aortic
valve was performed with a 20 mm balloon and a
23 mm Sapien 3 valve (Edwards Lifesciences, Irvine,
CA) was implanted under rapid ventricular pacing
(Fig. 2a). The intraoperative TEE showed a very
good aortic valve function without paravalvular
regurgitation (Fig. 2b).
Fig. 1 a Pre-operative CT-Scan: Severe calcification and dilation of left atrium. b CT-reconstruction with volume-rendering of the left-ventricular
outflow tract: aorto-mitral angle of 109°. c TEE LVOT view in diastole, showing severe mitral valve stenosis and narrowing of the LVOT
due to bulging of the inter-ventricular septum. d TEE 3D reconstruction of the native mitral valve during diastole showing severely
decreased residual effective orifice area
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Following the aortic valve procedure, repeated mitral
balloon valvuloplasty was attempted using first a 28 mm
Inoue balloon inserted through the apex and then a
30 mm Osypka balloon (Fig. 3a). The echocardiography
showed a slight decrease of the mitral valve gradient to a
mean value of 9 mmHg, but a moderate mitral valve
regurgitation. Due to the insufficient dilatation of the
mitral valve an attempt was undertaken to implant a
27 mm repositionable Lotus Valve System (Boston
Scientific, Marlborough, MA) without sheath, directly
through the exposed apex (Fig. 3b).
Immediately after the implantation of the Lotus valve,
the patient developed profound hypotension. On echo-
cardiography, severe obstruction of the left ventricular
outflow tract (LVOT) due to anterior displacement of
the thickened and partially calcified anterior native
mitral valve leaflet was detected (Fig. 3c/d). The Lotus
valve was partially recaptured and a second implantation
was attempted with the valve positioned slightly higher
into the left atrium, but LVOT-obstruction persisted.
The valve was removed, leaving the native mitral valve
with a transvalvular gradient of 4 mmHg, with mild
mitral valve regurgitation.
The patient was extubated in the hybrid room and had
an uneventful recovery. She was discharged to the
rehabilitation clinic 9 days after the procedure. Echocar-
diography at one month showed mild aortic regurgita-
tion and a moderate mitral valve stenosis with a mean
gradient of 8 mmHg. Furthermore, the patient reported
about an improvement of physical capacity after the
intervention and rehabilitation.
Discussion and conclusion
The development of transcatheter heart valves has led to
profound changes in the treatment of valvular heart
diseases. However, severe mitral valve stenosis is still
challenging to treat percutaneously, as limited experi-
ence exists for transcatheter mitral valve implantation
[7]. The calcification pattern commonly involves the
valve leaflets, the annulus and the subvalvular appar-
atus. This represents a risk for LVOT obstruction [8].
The clinical experience with combined transapical
transcatheter aortic and mitral valve replacement, is
limited. In 2015 Akujuo reported a similar case [2].
The procedure requires careful planning, including
precise morphological assessment with TEE and
multi-slice CT. The procedure itself must be carefully
guided by echocardiography and fluoroscopy. Espe-
cially the position of the mitral valved stent is crucial:
if it is too low in the left ventricular cavity it may result in
LVOT obstruction, if it is too high it increases the
probability of thrombogenic complications in the left
atrium [7, 8]. Morphology of the anterior mitral leaf-
let is important since following transcatheter place-
ment, it can obstruct the LVOT. The success of the
TA-MVI procedure depends on the correct deploy-
ment of the device, with the valve stent frame
extending equally in the left ventricle and in the left
atrium.
The obstruction of the LVOT is a critical complica-
tion after TAMVI. The anterior leaflet of the mitral
valve can potentially obstruct the LVOT by the
implanted transcatheter valve. Therefore, preoperative
CT analysis is mandatory to identify risk factors for
LVOT obstruction: left ventricular hypertrophy, in-
creased septal thickness, aorto-mitral angle of <90°
(AMA), small ventricular cavity and long anterior
mitral leaflet. Other important factors are the selected
valve and depth of implantation towards the left
ventricle in relation to the mitral annulus [8, 9].
Fig. 2 a Transapical deployment of the 23 mm Sapien 3 bioprosthesis in aortic position. b LVOT view showing minimal paravalvular regurgitation
after successful implantation of an Edwards Sapien 3 23 mm valve in aortic position
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Our case emphasizes the importance of a most precise
pre- and intra-procedural imaging to assess potential
problems associated with the deployment of the trans-
catheter valves. Furthermore, the use of 3D models and
printing for preoperative planning might help to reduce
per-interventional complications and even improve out-
come in high risk cases. In our patient, the LVOT was
judged to be narrowed and the mitral valve morphology
risky for LVOT obstruction. Accordingly, we decided
against the use of the balloon-expandable Edwards
Sapien 3 valve since, it is not repositionable and may
have led to lethal LVOT obstruction. The decision to
use the Lotus valve for this off-label indication was able
to prevent irreversible hemodynamic compromise due to
LVOT obstruction.
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